Nuvation Bio Stock Dips on $200 Million Convertible Notes Offering

By EC Assets · Published 25 June 2026

Nuvation Bio Inc. shares declined after the oncology company announced a planned offering of convertible senior notes. The company intends to offer $200 million in aggregate principal amount of these notes due in 2032. Nuvation Bio Inc. stock fell 11.8% in premarket trading on Thursday. The notes are due on July 1, 2032. Upon conversion, Nuvation Bio has the option to deliver cash, shares of its Class A common stock, or a combination of both. The choice of settlement method rests with the company. Nuvation Bio trades under the ticker NUVB on the NYSE. This article is intended for informational purposes only. It does not constitute investment advice.